Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03999229 · ClinicalTrials.gov registry record · Phase 1
S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion
A Phase 1 study of Transfusion Related Complication, sponsored by James Reynolds.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT03999229: Recruiting Phase 1 study of Transfusion Related Complication, sponsored by James Reynolds.
NCT03999229 is a Phase 1 study of Transfusion Related Complication that is actively recruiting participants, run by James Reynolds. The registered enrollment target is 35 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03999229, a Phase 1 study of Transfusion Related Complication, is actively recruiting participants, sponsored by James Reynolds.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The Purpose of the study is to test the hypothesis that administration of an S-nitrosylating (SNO) agent can improve tissue oxygenation during transfusion of packed red blood cells (RBCs).
Primary Outcome
Measurement of small vessel blood flow and oxygenation status with near infrared spectroscopy (NIRS). NIRS can record the amount of oxygenated and de-oxygenated hemoglobin (the main protein in red blood cells) using different light frequencies shined through probes attached to the skin. The tissue oxygenation measurement is expressed as a percentage based on the ratio of oxygenated to de-oxygenated hemoglobin. It is continually-measured to see if it is changing in response to transfusion or adm
Conditions Studied
Interventions
- DRUG Normal Saline
- DRUG SNO
- DRUG Red Blood Cell
Study Locations (1)
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2019-07-25 |
| Est. Completion | 2028-02-29 |
| Phase | Phase 1 |
What NCT03999229 shows while recruiting
NCT03999229 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Transfusion Related Complication appearing as the primary indexed condition, and to 3 interventions - of which Normal Saline is the first listed.
NCT03999229 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03999229 about?
NCT03999229 is a clinical study titled "S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion". The Purpose of the study is to test the hypothesis that administration of an S-nitrosylating (SNO) agent can improve tissue oxygenation during transfusion of packed red blood cells (RBCs).
What is the current status of trial NCT03999229?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2019-07-25. Estimated completion is 2028-02-29.
What conditions does trial NCT03999229 study?
This clinical trial studies the following conditions: Transfusion Related Complication.
What interventions are being tested in trial NCT03999229?
The interventions under investigation include: Normal Saline (DRUG), SNO (DRUG), Red Blood Cell (DRUG).
Who is sponsoring clinical trial NCT03999229?
This trial is sponsored by James Reynolds, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03999229 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03999229's enrollment target sits among peer trials
35 1258th of 2000 higher than 728 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI